Prelude Therapeutics (PRLD) FCF Margin (2024 - 2026)

Prelude Therapeutics (PRLD) reported FCF Margin of 473.47% for Q1 2026, down 215.51% sequentially from 409.91% in Q4 2025.

Prelude Therapeutics (PRLD) FCF Margin (2024 - 2026) Analysis & Trends

Prelude Therapeutics (PRLD) has 3 years of FCF Margin data on file, last reported at 473.47% in Q1 2026.

For the quarter ending Q1 2026, FCF Margin changed N/A year-over-year to 473.47%; the trailing twelve-month figure through Mar 2026 stood at 261.82% (changed N/A YoY), and the FY2025 full-year result was 464.32%, up 100565.0% from the prior year.
FCF Margin eased to 473.47% in Q1 2026, from 409.91% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 409.91% in Q4 2025 to a low of 911.97% in Q3 2024.
A 3-year average of 354.14% and a median of 473.47% in 2026 frame the typical range for FCF Margin.
Peak annual rise in FCF Margin reached 91099 bps in 2025, while the deepest fall reached 61789 bps in 2025.
Tracing PRLD's FCF Margin over 3 years: stood at 501.08% in 2024, then soared by 182 bps to 409.91% in 2025, then sank by 216 bps to 473.47% in 2026.
Business Quant data shows PRLD's FCF Margin at 473.47% in Q1 2026, 409.91% in Q4 2025, and 294.08% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Prelude Therapeutics	324.30 Mn	179.71 Mn	-	-473.47%

Download Data